Bisoprolol Fumarate And Hydrochlorothiazide Tablet, Film Coated
Product Images NDC 42799-922

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Bisoprolol Fumarate And Hydrochlorothiazide (NDC 42799-922). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Edenbridge Pharmaceuticals Llc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

10mg 30 (10 mg 30 Count)

Packaging label for Bisoprolol Fumarate and Hydrochlorothiazide Tablets, USP 10 mg/6.25 mg, film-coated tablets. The label indicates a package of 30 tablets, unit-of-use packaging. It includes dosing instructions, storage conditions, and the manufacturer Edenbridge Pharmaceuticals LLC, Parsippany, New Jersey.*

FDA Label Image

10mg 500 (10 mg 500 Count)

Packaging label for Bisoprolol Fumarate and Hydrochlorothiazide Tablets, USP 10 mg/6.25 mg, film-coated tablets by Edenbridge Pharmaceuticals LLC. The label shows a bottle containing 500 tablets, labeled as Rx only. It includes storage instructions and dosage directions to consult the package insert.*

FDA Label Image

10mg 100ct

Box label for Bisoprolol Fumarate and Hydrochlorothiazide Tablets, USP 10 mg/6.25 mg film-coated tablets. The label shows the product name, strength, count of 100 tablets, and the manufacturer Edenbridge Pharmaceuticals LLC. It includes storage instructions, dosage directions referencing package insert, and a barcode.*

FDA Label Image

25 100 (25 mg 100 Count)

Bisoprolol Fumarate and Hydrochlorothiazide Tablets, USP 2.5 mg/6.25 mg film-coated tablets in a white and blue box. The label states 100 tablets, prescription only, manufactured by Edenbridge Pharmaceuticals LLC, with batch and storage instructions, and an NDC of 42799-920-01.*

FDA Label Image

25mg 30 (25 mg 30 Count)

The packaging label of Bisoprolol Fumarate and Hydrochlorothiazide Tablets, USP 2.5 mg/6.25 mg, film-coated tablets. The label indicates a 30-tablet unit-of-use package, marked for prescription use only (Rx only). It includes a barcode, storage instructions at 20° to 25°C, and manufacturer information, Edenbridge Pharmaceuticals LLC, Parsippany, New Jersey.*

FDA Label Image

25 500 (25 mg 500 Count)

Packaging label for Bisoprolol Fumarate and Hydrochlorothiazide Tablets USP 2.5 mg/6.25 mg by Edenbridge Pharmaceuticals LLC. The label indicates a bottle containing 500 film-coated tablets for oral use, with NDC 42799-920-02. Storage and dispensing instructions and manufacturer details are provided.*

FDA Label Image

5mg 100 (5 mg 100 Count)

Packaging label for Bisoprolol Fumarate and Hydrochlorothiazide Tablets, USP, 5 mg/6.25 mg, film-coated oral tablets. The label shows a package count of 100 tablets, marked for prescription use only, manufactured by Edenbridge Pharmaceuticals LLC, Parsippany, New Jersey. Dosage instructions and storage information are partly visible.*

FDA Label Image

5mg 30 (5 mg 30 Count)

Packaging label for Bisoprolol Fumarate and Hydrochlorothiazide Tablets, USP 5 mg/6.25 mg, film-coated tablets in a container of 30 tablets. The label includes dosage instructions, storage conditions, and manufacturer information, Edenbridge Pharmaceuticals LLC, Parsippany, New Jersey.*

FDA Label Image

5mg 500 (5 mg 500 Count)

Label for Bisoprolol Fumarate and Hydrochlorothiazide Tablets, USP 5 mg/6.25 mg, film-coated oral tablets. The label indicates a package size of 500 tablets, with the product manufactured by Edenbridge Pharmaceuticals LLC, Parsippany, New Jersey. The label includes dosage strengths and storage instructions, along with a barcode and the NDC number 42799-921-02.*

FDA Label Image

Biso Api Structure (Api Pic New1)

Chemical structure of Bisoprolol Fumarate and Hydrochlorothiazide, depicting molecular components and bonds associated with the active ingredients in the combination drug.*

FDA Label Image

Hctz Api Structure (Api Pic New2)

Chemical structure of the active ingredient bisoprolol fumarate and hydrochlorothiazide, shown as a molecular diagram with labeled atoms and chemical bonds.*

FDA Label Image

Table 1 (Table 1 New)

Data table presenting the mean decrease in sitting systolic/diastolic blood pressure and heart rate after 3-4 weeks in two studies comparing placebo and various doses of Bisoprolol Fumarate and Hydrochlorothiazide. The table includes sample sizes, total blood pressure and heart rate changes, and drug-specific effects.*

FDA Label Image

Table-3 (Table 3 New)

A data table showing the percentage of patients experiencing various adverse experiences categorized by body system, comparing placebo versus Bisoprolol Fumarate and Hydrochlorothiazide 10;6.25 mg/1; mg/1 treatment groups. It includes all adverse experiences and drug-related adverse experiences across cardiovascular, respiratory, body as a whole, central nervous system, musculoskeletal, psychiatric, and gastrointestinal categories.*

FDA Label Image

Table-2 (Table New 2)

A table titled 'Serum Potassium Data from U.S. Placebo Controlled Studies' showing data on potassium levels and hypokalemia incidence across placebo and various doses of a drug. Columns list groups: Placebo, B2.5/H6.25 mg, B5/H6.25 mg, B10/H6.25 mg, and Duzela 25 mg, with corresponding sample sizes. Rows present mean change in potassium (mEq/L) and percentage of hypokalemia for each group.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.